U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    49,239.69
    +1,583.96 (+3.32%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Purigen Biosystems Enables Scientists to Extract and Purify Higher Yields of DNA from Fresh Frozen Tissue Samples

·3 min read

New automated Ionic® Tissue to Pure DNA Kit recovers more than three times the amount of high-quality nucleic acid from limited samples compared to leading column-based products

PLEASANTON, Calif., October 19, 2021--(BUSINESS WIRE)--Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic® Tissue to Pure DNA Kit. The new kit allows users of the Ionic® Purification System to extract increased yields of high-quality DNA from fresh frozen biological samples with a simple, automated workflow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005342/en/

Purigen Biosystems' automated Ionic® Tissue to Pure DNA Kit recovers more than three times the amount of high-quality nucleic acid from limited samples compared to leading column-based products. (Photo: Business Wire)

The Ionic Tissue to Pure DNA Kit consistently provides more than three times higher DNA yields compared to leading column-based kits. It also features a simple, automated workflow that requires only five minutes of hands-on time per sample. The kit works with limited biological samples and ensures that sufficient amounts of nucleic acid are available for all necessary downstream analysis techniques, such as next-generation sequencing and qPCR.

"Unlocking the most information possible from precious and limited samples has been a longstanding and critical challenge for oncology researchers," said Barney E. Saunders, PhD, CEO of Purigen Biosystems. "We are moving rapidly to address this challenge and the Ionic Tissue to Pure DNA Kit, combined with our existing portfolio of kits for FFPE tissue samples, represents a fundamental change in the efficiency of nucleic acid extraction. More abundant and higher-quality nucleic acids allow for superior next-generation sequencing data."

The Ionic Tissue to Pure DNA Kit utilizes Purigen’s Ionic Purification System, a benchtop instrument that enables the automated extraction of pure and abundant nucleic acids from a wide range of sample types, including cultured or sorted cells and FFPE tissue. These biological samples are gently lysed and loaded into an Ionic® Fluidic Chip. The Ionic System uses the company’s innovative isotachophoresis (ITP) technology to apply an electric field to the chip, which isolates the nucleic acids in their natural, native form. Since the nucleic acids are not denatured or dehydrated, nor are they bound and stripped from fixed surfaces, the process minimizes fragmentation and eliminates bead or buffer contamination.

The Ionic Tissue to Pure DNA Purification Kit consists of six chips and a reagent set with all necessary enzymes and buffers to perform DNA extraction from 48 samples. The kit is available now through Purigen’s direct sales channels. For more information, please visit: purigenbio.com/tissue-DNA.

About Purigen Biosystems

Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on the highly efficient isotachophoresis technology invented by Juan Santiago, PhD, and his team at Stanford University. Purigen’s automated benchtop instrument and accompanying microfluidic chip purify nucleic acid samples from a wide variety of sources, including minute or otherwise challenging cancer samples. The purified nucleic acids are then immediately compatible with a wide range of downstream detection methods, including next-generation sequencing, PCR, and other genomic tests. For more information, visit www.purigenbio.com.

Ionic is a registered trademark of Purigen Biosystems, Inc. All other trademarks are the property of their respective owners. All products described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005342/en/

Contacts

Andrew Noble
415-722-2129
andrew@bioscribe.com